PROTAC induced-BET protein degradation exhibits potent anti-osteosarcoma activity by triggering apoptosis
出版年份 2019 全文链接
标题
PROTAC induced-BET protein degradation exhibits potent anti-osteosarcoma activity by triggering apoptosis
作者
关键词
-
出版物
Cell Death & Disease
Volume 10, Issue 11, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-10-26
DOI
10.1038/s41419-019-2022-2
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Experimental Characterization of the Binding Affinities between Proapoptotic BH3 Peptides and Antiapoptotic Bcl-2 Proteins
- (2018) Wenna Kong et al. ChemMedChem
- Inhibition of Mcl-1 enhances Pevonedistat-triggered apoptosis in osteosarcoma cells
- (2017) Yi Zhang et al. EXPERIMENTAL CELL RESEARCH
- Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression
- (2017) Bing Zhou et al. JOURNAL OF MEDICINAL CHEMISTRY
- Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells
- (2017) D T Saenz et al. LEUKEMIA
- Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia
- (2017) S Peirs et al. LEUKEMIA
- PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
- (2016) Kanak Raina et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Broad targeting of resistance to apoptosis in cancer
- (2015) Ramzi M. Mohammad et al. SEMINARS IN CANCER BIOLOGY
- BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells
- (2015) Emma K Baker et al. Scientific Reports
- BET bromodomain protein inhibition is a therapeutic option for medulloblastoma
- (2015) Anton George Henssen et al. Oncotarget
- Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma
- (2014) Dhong Hyun Lee et al. INTERNATIONAL JOURNAL OF CANCER
- BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD
- (2014) W. Fiskus et al. MOLECULAR CANCER THERAPEUTICS
- Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle
- (2014) François Lamoureux et al. Nature Communications
- Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
- (2014) M. Hidalgo et al. Cancer Discovery
- MicroRNA-133a, downregulated in osteosarcoma, suppresses proliferation and promotes apoptosis by targeting Bcl-xL and Mcl-1
- (2013) Fang Ji et al. BONE
- Osteosarcoma treatment – Where do we stand? A state of the art review
- (2013) Anja Luetke et al. CANCER TREATMENT REVIEWS
- Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
- (2013) Jakob Lovén et al. CELL
- Rise of the Selective Inhibitors of Anti-Apoptotic Bcl-2 Family Proteins
- (2013) Li Han et al. ChemMedChem
- BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1
- (2013) Helen Jayne Susan Stewart et al. Cancer Medicine
- Functional and biological analysis of Bcl-xL expression in human osteosarcoma
- (2010) Zhao-Xia Wang et al. BONE
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
- The ubiquitin pathway: An emerging drug target in cancer therapy
- (2009) Sudharsana Rao Ande et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Molecular Details of Bax Activation, Oligomerization, and Membrane Insertion
- (2009) Stephanie Bleicken et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started